Unknown

Dataset Information

0

Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models.

ABSTRACT:

SUBMITTER: Charest A 

PROVIDER: S-EPMC8917392 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models.

Charest Alain A  

Neuro-oncology 20220301 3

Similar Datasets

Unknown Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study.
| S-EPMC10942024 | biostudies-literature
Unknown The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models.
| S-EPMC10244095 | biostudies-literature
Unknown Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
| S-EPMC8917401 | biostudies-literature
Unknown Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.
| S-EPMC11450402 | biostudies-literature
Unknown EphA3 CAR T cells are effective against glioblastoma in preclinical models.
| S-EPMC11308892 | biostudies-literature
Unknown Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma.
| S-EPMC8116896 | biostudies-literature
Unknown Pelophen B is a non-taxoid binding microtubule-stabilizing agent with promising preclinical anticancer properties.
| S-EPMC11618378 | biostudies-literature
Unknown Adjuvant therapeutic potential of tonabersat in the standard treatment of glioblastoma: A preclinical F98 glioblastoma rat model study.
| S-EPMC6802836 | biostudies-literature
Unknown ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme.
| S-EPMC5010991 | biostudies-literature
Unknown Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
| S-EPMC4818716 | biostudies-literature